Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk: A Paradigm Shift |
- 1.50 CDE
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation
|
Enduring |
|
$0.00 |
The Burden of Resistant Hypertension in Women: Novel and Emerging Approaches to Improve Outcomes |
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
|
Enduring |
|
$0.00 |
Challenges and Solutions in Lipid-Lowering Therapy in Women: From Gaps to Practice-Changing Advances |
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation
|
Enduring |
|
$0.00 |
Breaking Through Inertia: How to Initiate and Maintain Insulin Therapy in Patients with Type 2 Diabetes |
- 1.50 AAFP
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
|
Enduring |
|
$0.00 |
Advances in Managing Eosinophilic Esophagitis: Tips for the Practicing Clinician |
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
|
Enduring |
|
$0.00 |
The Risk Stratification and Treatment of Chronic Kidney Disease in Women: Uncovering and Addressing Disparities to Improve Outcomes |
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |
Cannabinoid Clinical Applications |
|
Enduring |
|
$49.00 |
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis |
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
|
Enduring |
|
$0.00 |
Ace the Case Challenge Series: Sodium Intake and CV Risk |
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation
|
Enduring |
|
$0.00 |
Cannabinoids and Pain Management |
|
Enduring |
|
$49.00 |
According to the Patient: Alopecia Areata in Adolescence |
- 1.00 AAPA Category I CME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |
Addressing the Burden of Cardiovascular Comorbidities in Narcolepsy: Strategies and Perspectives to Optimize Treatment and Patient Outcomes |
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |
Pharmaceutical & Commercial Cannabinoid Products |
|
Enduring |
|
$49.00 |
Expanding the Therapeutic “AHR”senal for Pediatric Atopic Dermatitis |
- 1.00 AAPA Category I CME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |
AhR Agonists for Psoriasis: A Novel Mechanism for Treatment of PsO |
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |